Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal beta-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia A Randomized Clinical Trial
Steven Y. C. Tong, D. Lye, D. Yahav, Archana Sud, J. O. Robinson, J. Nelson, Sophia Archuleta, Matthew A. Roberts, A. Cass, David L. Paterson, Hong Foo, Mical Paul, Stephen D. Guy, A. Tramontana, G. Walls, Stephen McBride, N. Bak, N. Ghosh, Benjamin A. Rogers, Anna P. Ralph, Jane Davies, P. Ferguson, R. Dotel, Genevieve L. Mckew, T. Gray, N. E. Holmes, Simon Smith, M. Warner, S. Kalimuddin, B. Young and 13 others
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
No abstract is available from our sources. Use “Read paper” to view it.
TL;DRAdding an antistaphylococcal β-lactam to standard antibiotic therapy with vancomycin or daptomycin did not result in significant improvement in the primary composite end point of mortality, persistent bacteremia, relapse, or treatment failure among patients with MRSA baiteremia. (Semantic Scholar)